Edwards Lifesciences Q1 2026 Results Beat Expectations and Raise Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Should l Buy EW?
Source: seekingalpha
- Strong Earnings Beat: Edwards Lifesciences reported Q1 2026 revenue of $1.65 billion, exceeding market expectations by $50 million, showcasing robust performance in the transcatheter aortic valve replacement sector.
- Guidance Upgrade: The company raised its full-year revenue guidance to $6.5 billion to $6.9 billion, surpassing the consensus estimate of $6.67 billion, reflecting optimistic expectations for future market demand.
- Adjusted EPS Increase: The midpoint of the adjusted EPS guidance was raised to $2.95 to $3.05 from the previous $2.90 to $3.05, indicating ongoing improvements in profitability.
- Healthy Cash Position: As of the end of Q1 2026, the company reported cash and cash equivalents of approximately $2.4 billion, providing ample financial support for future investments and operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EW
Wall Street analysts forecast EW stock price to rise
24 Analyst Rating
16 Buy
8 Hold
0 Sell
Moderate Buy
Current: 82.760
Low
84.00
Averages
96.52
High
105.00
Current: 82.760
Low
84.00
Averages
96.52
High
105.00
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Opportunities in Asian Small Caps
- Market Resilience: Amid global economic shifts, Asian markets have shown strong resilience, with Chinese equities advancing and Japan's indices reaching record highs, reflecting optimism in the technology and semiconductor sectors, potentially providing a favorable entry point for investors.
- Small Cap Potential: Cedar Woods Properties is projected to achieve a 30% to 35% NPAT growth for fiscal year 2026, holding a market cap of A$0.35 billion, with over half of its fiscal year 2027 revenue already presold, indicating strong market confidence and future growth potential.
- Strong Financial Performance: Smartgroup's sales grew from A$305.8 million to A$329.31 million in fiscal year 2025, with net income rising from A$75.6 million to A$79.44 million, showcasing growth potential in the financial services sector, further bolstered by insider share purchases that enhance market confidence.
- Coal Sector Dynamics: Semirara Mining and Power reported a Q1 2026 revenue of PHP 15.4 billion, a year-over-year decline, yet coal production increased by 4% due to improved mining conditions, demonstrating growth potential amidst a volatile market environment.
See More
Edwards Lifesciences Appoints New CFO
- Executive Appointment: Edwards Lifesciences has announced the appointment of Theodora Mistras as Chief Financial Officer effective at the end of May, succeeding Scott Ullem, who will remain in an advisory role to ensure continuity in financial management.
- Background Overview: Prior to joining Edwards, Mistras served as CFO at Viatris since March 2024 and was a managing director in healthcare investment banking at Citigroup, bringing extensive financial and investment expertise to the role.
- Strategic Implications: Mistras's appointment aims to leverage her deep background in the healthcare sector and financial management skills to drive continued growth and innovation for Edwards in the cardiovascular medical device market.
- Transition Support: Scott Ullem's ongoing involvement will provide Mistras with essential support and guidance, ensuring that the company's strategic direction and financial stability remain unaffected during the executive transition.
See More
Edwards Lifesciences Appoints New Executive
- Executive Appointment: Edwards Lifesciences announced late Monday the appointment of Theodora Mistras as corporate vice president, a move aimed at strengthening the leadership team and enhancing strategic execution capabilities.
- Strategic Implications: Mistras's addition is expected to bring new perspectives and experience, particularly in innovation and market expansion within the medical device sector, further driving the company's business growth.
- Leadership Team Optimization: This appointment reflects the company's commitment to diversity and expertise within its executive team, aiming to enhance market competitiveness by introducing leaders with extensive industry experience.
- Future Outlook: As the healthcare industry rapidly evolves, Edwards Lifesciences aims to adapt to market changes through such executive transitions, ensuring it remains at the forefront of technological innovation and customer demand.
See More
Edwards Lifesciences Appoints New CFO
- New CFO Appointment: Edwards Lifesciences has announced the appointment of Theodora Mistras as Chief Financial Officer effective at the end of May 2026, succeeding Scott Ullem, who has served in the role for over a decade, indicating a strategic transition in leadership.
- Extensive Financial Background: Mistras joins from Viatris, where she served as CFO since 2024, and has significant experience in healthcare finance from her roles at Citigroup Global Markets and Goldman Sachs, which will enhance the company's financial strategy.
- Sales Growth Forecast: Edwards Lifesciences anticipates a sales growth of 9%-11% for 2026, with adjusted earnings per share projected between $2.95 and $3.05, reflecting strong confidence in market demand and operational performance.
- TAVR Guidance Increase: The company has raised its transcatheter aortic valve replacement (TAVR) guidance to a range of 7%-9%, indicating increased product demand and potential for further revenue growth and market share expansion.
See More
EDWARDS LIFESCIENCES NAMES NEW CFO
- Announcement of Appointment: Edward S. Life Sciences has announced the appointment of a new Chief Financial Officer (CFO).
- Significance of the Appointment: The new CFO is expected to bring valuable expertise and leadership to the company's financial operations.
See More
Edwards Lifesciences Announces 10-Year COMMENCE Trial Results
- Long-Term Durability Evidence: The 10-year data from the COMMENCE trial shows that patients treated with surgical valves featuring RESILIA tissue have a 97.9% freedom from structural valve deterioration (SVD), indicating not only the long-term durability of this technology but also its potential to reduce the need for repeat procedures, thereby enhancing quality of life.
- Hope for Younger Patients: Despite enrolling younger patients who historically face higher risks of valve deterioration, the trial reported a 97.8% freedom from reoperation and a 98.6% freedom from non-structural valve dysfunction, underscoring the potential of RESILIA tissue to change treatment decision-making for physicians.
- Industry Leadership: With nearly 70 years of experience in structural heart innovation, Edwards Lifesciences reinforces its position as a standard-bearer in evaluating valve performance and durability through the COMMENCE trial, which supports its clinical evidence for surgical and transcatheter therapies.
- Ongoing Technological Advancements: Designed to enhance the durability of tissue valves, RESILIA tissue employs advanced calcium blocking processes and dry storage, and as patient lifespans increase, the continuous development of this technology will provide more reliable long-term treatment options for heart teams and patients.
See More
Investment Opportunities in Asian Small Caps
- Market Resilience: Amid global economic shifts, Asian markets have shown strong resilience, with Chinese equities advancing and Japan's indices reaching record highs, reflecting optimism in the technology and semiconductor sectors, potentially providing a favorable entry point for investors.
- Small Cap Potential: Cedar Woods Properties is projected to achieve a 30% to 35% NPAT growth for fiscal year 2026, holding a market cap of A$0.35 billion, with over half of its fiscal year 2027 revenue already presold, indicating strong market confidence and future growth potential.
- Strong Financial Performance: Smartgroup's sales grew from A$305.8 million to A$329.31 million in fiscal year 2025, with net income rising from A$75.6 million to A$79.44 million, showcasing growth potential in the financial services sector, further bolstered by insider share purchases that enhance market confidence.
- Coal Sector Dynamics: Semirara Mining and Power reported a Q1 2026 revenue of PHP 15.4 billion, a year-over-year decline, yet coal production increased by 4% due to improved mining conditions, demonstrating growth potential amidst a volatile market environment.
See More
Edwards Lifesciences Appoints New CFO
- Executive Appointment: Edwards Lifesciences has announced the appointment of Theodora Mistras as Chief Financial Officer effective at the end of May, succeeding Scott Ullem, who will remain in an advisory role to ensure continuity in financial management.
- Background Overview: Prior to joining Edwards, Mistras served as CFO at Viatris since March 2024 and was a managing director in healthcare investment banking at Citigroup, bringing extensive financial and investment expertise to the role.
- Strategic Implications: Mistras's appointment aims to leverage her deep background in the healthcare sector and financial management skills to drive continued growth and innovation for Edwards in the cardiovascular medical device market.
- Transition Support: Scott Ullem's ongoing involvement will provide Mistras with essential support and guidance, ensuring that the company's strategic direction and financial stability remain unaffected during the executive transition.
See More
Edwards Lifesciences Appoints New Executive
- Executive Appointment: Edwards Lifesciences announced late Monday the appointment of Theodora Mistras as corporate vice president, a move aimed at strengthening the leadership team and enhancing strategic execution capabilities.
- Strategic Implications: Mistras's addition is expected to bring new perspectives and experience, particularly in innovation and market expansion within the medical device sector, further driving the company's business growth.
- Leadership Team Optimization: This appointment reflects the company's commitment to diversity and expertise within its executive team, aiming to enhance market competitiveness by introducing leaders with extensive industry experience.
- Future Outlook: As the healthcare industry rapidly evolves, Edwards Lifesciences aims to adapt to market changes through such executive transitions, ensuring it remains at the forefront of technological innovation and customer demand.
See More
Edwards Lifesciences Appoints New CFO
- New CFO Appointment: Edwards Lifesciences has announced the appointment of Theodora Mistras as Chief Financial Officer effective at the end of May 2026, succeeding Scott Ullem, who has served in the role for over a decade, indicating a strategic transition in leadership.
- Extensive Financial Background: Mistras joins from Viatris, where she served as CFO since 2024, and has significant experience in healthcare finance from her roles at Citigroup Global Markets and Goldman Sachs, which will enhance the company's financial strategy.
- Sales Growth Forecast: Edwards Lifesciences anticipates a sales growth of 9%-11% for 2026, with adjusted earnings per share projected between $2.95 and $3.05, reflecting strong confidence in market demand and operational performance.
- TAVR Guidance Increase: The company has raised its transcatheter aortic valve replacement (TAVR) guidance to a range of 7%-9%, indicating increased product demand and potential for further revenue growth and market share expansion.
See More
EDWARDS LIFESCIENCES NAMES NEW CFO
- Announcement of Appointment: Edward S. Life Sciences has announced the appointment of a new Chief Financial Officer (CFO).
- Significance of the Appointment: The new CFO is expected to bring valuable expertise and leadership to the company's financial operations.
See More
Edwards Lifesciences Announces 10-Year COMMENCE Trial Results
- Long-Term Durability Evidence: The 10-year data from the COMMENCE trial shows that patients treated with surgical valves featuring RESILIA tissue have a 97.9% freedom from structural valve deterioration (SVD), indicating not only the long-term durability of this technology but also its potential to reduce the need for repeat procedures, thereby enhancing quality of life.
- Hope for Younger Patients: Despite enrolling younger patients who historically face higher risks of valve deterioration, the trial reported a 97.8% freedom from reoperation and a 98.6% freedom from non-structural valve dysfunction, underscoring the potential of RESILIA tissue to change treatment decision-making for physicians.
- Industry Leadership: With nearly 70 years of experience in structural heart innovation, Edwards Lifesciences reinforces its position as a standard-bearer in evaluating valve performance and durability through the COMMENCE trial, which supports its clinical evidence for surgical and transcatheter therapies.
- Ongoing Technological Advancements: Designed to enhance the durability of tissue valves, RESILIA tissue employs advanced calcium blocking processes and dry storage, and as patient lifespans increase, the continuous development of this technology will provide more reliable long-term treatment options for heart teams and patients.
See More
